External validation of biomarkers for immune-related adverse events after immune checkpoint inhibition

Immune checkpoint inhibitors have revolutionized treatment of advanced melanoma, but commonly cause serious immune-mediated complications. The clinical ambition of reserving more aggressive therapies for patients least likely to experience immune-related adverse events (irAE) has driven an extensive...

Descripción completa

Detalles Bibliográficos
Autores principales: Glehr, Gunther, Riquelme, Paloma, Yang Zhou, Jordi, Cordero, Laura, Schilling, Hannah-Lou, Kapinsky, Michael, Schlitt, Hans J., Geissler, Edward K., Burkhardt, Ralph, Schmidt, Barbara, Haferkamp, Sebastian, Hutchinson, James A., Kronenberg, Katharina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9556693/
https://www.ncbi.nlm.nih.gov/pubmed/36248910
http://dx.doi.org/10.3389/fimmu.2022.1011040

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9556693/
https://www.ncbi.nlm.nih.gov/pubmed/36248910
http://dx.doi.org/10.3389/fimmu.2022.1011040

Ejemplares similares